Adicet Bio, Inc. filed a Form 8-K on November 13, 2026, disclosing the resignation of board director Andrew Sinclair, Ph.D., and a related committee appointment, with both actions effective November 13, 2026.

Key Highlights

  • Resignation effective November 13, 2026: Andrew Sinclair, Ph.D., a Class III board member, resigned from the board of directors, the Audit Committee, and the Nominating and Corporate Governance Committee.
  • No disagreement cited: According to the filing, Dr. Sinclair's resignation "was not the result of any disagreement with management or the Board or on any matter relating to the Company's operations, policies or practices."
  • Board size reduced: The filing states the board will be reduced from seven to six members upon Dr. Sinclair's departure.
  • Grissinger joins Audit Committee: Current director Michael Grissinger was appointed to serve on the Audit Committee, effective November 13, 2026.
  • Grissinger named NCG Committee chair: Michael Grissinger was also appointed to serve as chairperson of the Nominating and Corporate Governance Committee.
  • Independence determination: The board determined that Mr. Grissinger meets independence requirements for audit committee members under Nasdaq listing standards and the Securities and Exchange Act of 1934.

Board Composition Changes at Adicet Bio Following Sinclair Departure

Adicet Bio, Inc. (NASDAQ:ACET) reported a director departure and related committee changes in its November 13, 2026 current report. Andrew Sinclair, Ph.D., who served as a Class III member of the board, notified the company on November 11, 2026 of his intent to resign, with the resignation becoming effective November 13, 2026. The filing states his departure was not tied to any disagreement with management or the board on any matter relating to the company's operations, policies, or practices.

As a consequence of the resignation, the company disclosed that the size of the board would decrease from seven directors to six. Dr. Sinclair's departure also vacated his seats on the Audit Committee and the Nominating and Corporate Governance Committee. To fill these committee roles, the board, upon recommendation of the NCG Committee, appointed current director Michael Grissinger to the Audit Committee and named him chairperson of the NCG Committee, both effective the same day.

The filing further noted that the board determined Mr. Grissinger satisfies the independence requirements for audit committee members under Nasdaq Capital Market listing standards and the Securities and Exchange Act of 1934, as amended. The report was signed by Nick Harvey, Chief Financial Officer of Adicet Bio, Inc.

What Was Disclosed

The filing disclosed the resignation of board director Andrew Sinclair, Ph.D., from Adicet Bio's board and two of its committees, effective November 13, 2026, along with the appointment of director Michael Grissinger to the Audit Committee and as NCG Committee chairperson.